{
    "clinical_study": {
        "@rank": "158025", 
        "acronym": "ETHYFYL", 
        "arm_group": {
            "arm_group_label": "Fentanyl / Placebo", 
            "arm_group_type": "Experimental", 
            "description": "After an open-label titration to identify an optimal dose, patients were randomized  to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when\n      used to relieve breakthrough pain (BTP) in opioid-treated cancer patients."
        }, 
        "brief_title": "Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Breakthrough Pain", 
            "Cancer"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Written informed consent\n\n          2. Malignant solid tumor or a hematological malignancy causing cancer-related pain\n\n          3. Background opioid treatment at a stable dose for at least a week\n\n          4. One to four episodes of breakthrough pain per day\n\n        Main exclusion criteria:\n\n          1. Hypersensitivity to fentanyl or to any of the excipients\n\n          2. Intrathecal opioids\n\n          3. Recent history of substance abuse\n\n          4. Recent or planned therapy that would alter pain\n\n          5. Moderate or severe hepatic or renal disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "91", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842893", 
            "org_study_id": "FYL/24019/008"
        }, 
        "intervention": {
            "arm_group_label": "Fentanyl / Placebo", 
            "description": "After an open-label titration to identify an optimal dose, patients were randomized  to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)", 
            "intervention_name": "Fentanyl Ethypharm", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fentanyl", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "fentanyl", 
            "breakthrough pain", 
            "opioid treated cancer patients"
        ], 
        "lastchanged_date": "May 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Prague", 
                    "country": "Czech Republic"
                }, 
                "name": "Pain Care Units"
            }
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "official_title": "Randomized, Placebo-controlled Study of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Czech Republic: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Summed Pain Intensity Difference at 30 minutes (SPID30).", 
            "safety_issue": "No", 
            "time_frame": "30 minutes post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842893"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "SPID at 3, 6, 10, 15 and 60 minutes post-dosing", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 10, 15 and 60 minutes post-dosing"
            }, 
            {
                "measure": "SPID at 15 and 30 minutes according to the pathophysiology of the pain (neuropathic, nociceptive)", 
                "safety_issue": "No", 
                "time_frame": "15 and 30 minutes post dose"
            }, 
            {
                "measure": "Pain Intensity Difference at 3, 6, 10, 15, 30 and 60 minutes after dosing", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 10, 15, 30 and 60 minutes after dosing"
            }, 
            {
                "measure": "Pain Relief at 3, 6, 10, 15, 30 and 60 minutes after dosing", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 10, 15, 30 and 60 minutes after dosing"
            }, 
            {
                "measure": "The proportion of episodes of BTP that required rescue medication", 
                "safety_issue": "No", 
                "time_frame": "15 and 30 minutes post dose"
            }, 
            {
                "measure": "the proportion of episodes with more than 33% and 50% of improvement in Pain Intensity scores", 
                "safety_issue": "No", 
                "time_frame": "15 and 30 minutes post dose"
            }, 
            {
                "description": "Adverse events, vital signs, urinary pregnancy test", 
                "measure": "Recording of safety data", 
                "safety_issue": "Yes", 
                "time_frame": "During all the study duration, an expected average of 8 weeks"
            }
        ], 
        "source": "Ethypharm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ethypharm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}